Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
Retrieved on:
Wednesday, September 15, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Prevalence, Trial of the century, Caregiver burden, Biomarker, Biotechnology, Mutation, Microglia, Immune system, Genetic testing, Neurodegeneration, Neuroscience, TREM2, Patient, Institute, Disease, Physician, Physical, Autosome, Lists of diseases, Diagnosis, Life, Life expectancy, University College London, Pharmaceutical industry, Medical imaging, VGL101, ALSP, Vigil Neuroscience, VGL101, ALSP, VIGIL NEUROSCIENCE
Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
Key Points:
- Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
- ALSP is a rare, genetically defined fatal neurodegenerative disease with strong mechanistic and biochemical associations to microglia dysfunction.
- This study is a key component in the development plan of our lead clinical candidate, VGL101, as a potential treatment option for ALSP patients.
- Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare, inherited, autosomal dominant neurological disease with high penetrance.